TY - JOUR
T1 - The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
AU - Moran, Amy E.
AU - Kovacsovics-Bankowski, Magdalena
AU - Weinberg, Andrew D.
N1 - Funding Information:
Supported by NIH grants RO1 CA102577 and CA122701 (M.K.B, A.D.W), DOD grant W81XWH-11-1-0345 (A.D.W.), and NIH T32 AI78903 training fellowship (A.E.M.). The authors wish to thank Walter J. Urba for critical reading of this manuscript.
PY - 2013/4
Y1 - 2013/4
N2 - T cell-mediated rejection of tumors requires signals from the T cell receptor and co-stimulatory molecules to license effector functions of tumor-antigen specific T cells. There is also an array of immune suppressive mechanisms within the tumor microenvironment that can suppress anti-tumor immunity. The use of monoclonal antibodies to overcome this suppression and/or enhance tumor-antigen specific T cell responses has shown promise in clinical trials. In particular, targeting co-stimulatory members of the tumor necrosis factor receptor (TNFR) family with agonist Abs enhances T cell function, which has led to encouraging therapeutic results in cancer-bearing hosts. These encouraging data establish TNFRs as important targets for enhancing tumor-specific immune responses in mice and man. This review will focus on agonists that target the TNFRs OX40, 4-1BB, and CD40.
AB - T cell-mediated rejection of tumors requires signals from the T cell receptor and co-stimulatory molecules to license effector functions of tumor-antigen specific T cells. There is also an array of immune suppressive mechanisms within the tumor microenvironment that can suppress anti-tumor immunity. The use of monoclonal antibodies to overcome this suppression and/or enhance tumor-antigen specific T cell responses has shown promise in clinical trials. In particular, targeting co-stimulatory members of the tumor necrosis factor receptor (TNFR) family with agonist Abs enhances T cell function, which has led to encouraging therapeutic results in cancer-bearing hosts. These encouraging data establish TNFRs as important targets for enhancing tumor-specific immune responses in mice and man. This review will focus on agonists that target the TNFRs OX40, 4-1BB, and CD40.
UR - http://www.scopus.com/inward/record.url?scp=84877059530&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877059530&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2013.01.004
DO - 10.1016/j.coi.2013.01.004
M3 - Review article
C2 - 23414607
AN - SCOPUS:84877059530
SN - 0952-7915
VL - 25
SP - 230
EP - 237
JO - Current opinion in immunology
JF - Current opinion in immunology
IS - 2
ER -